Register
WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19 |
News and Updates
eMediNexus Coverage from: 
WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19

7 Read Comments                

The World Health Organization (WHO) has accepted the recommendation from the Solidarity Trial International Steering Committee to terminate the hydroxychloroquine and lopinavir/ritonavir arms in the trial.

The recommendation was based on the evidence for hydroxychloroquine vs standard-of-care and for lopinavir/ritonavir vs standard-of-care from the Solidarity trial interim results, as well as a review of the evidence from all trials presented at the WHO Summit on COVID-19 research and innovation. The interim results suggest that hydroxychloroquine and lopinavir/ritonavir yield little or no reduction in the mortality among hospitalized COVID-19 patients, compared to standard of care… (WHO, July 4, 2020)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now